A Phase 1, Open-Label Study To Evaluate 5-HT2a Receptor Occupancy As Measured By Positron Emission Tomography (PET) With Ligand [11C]MDL100907 Following Single Oral Dose Administration Of PP-05212377 (SAM-760) In Healthy Subjects

Trial Profile

A Phase 1, Open-Label Study To Evaluate 5-HT2a Receptor Occupancy As Measured By Positron Emission Tomography (PET) With Ligand [11C]MDL100907 Following Single Oral Dose Administration Of PP-05212377 (SAM-760) In Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2014

At a glance

  • Drugs PF 5212377 (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 15 Apr 2014 Status changed from suspended to completed as reported by ClinicalTrials.gov record.
    • 01 Apr 2014 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov record.
    • 14 Feb 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top